M. Lemp, Report of the national eye institute/industry workshop on clinical trials in dry eyes, CLAO J, vol.21, pp.221-253, 1995.

S. Ugfelder, Prevalence, burden, and pharmacoeconomics of dry eye disease, Am J Manag Care, vol.14, pp.102-108, 2008.

V. Smith, H. Rishmawi, and H. Hussein, Tear film MMP accumulation and corneal disease, British Journal of Ophthalmology, vol.85, issue.2, pp.147-53, 2001.
DOI : 10.1136/bjo.85.2.147

URL : http://bjo.bmj.com/content/bjophthalmol/85/2/147.full.pdf

B. Yüksel, B. Bozda?, and M. Acar, Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients, Eur J Ophthalmol, vol.20, pp.675-684, 2010.

K. Stevenson, O. Mundorf, and T. , Two multicenter, randomized studies of the ef cacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group, Ophthalmology, vol.107, pp.631-640, 2000.

R. Schiffman, M. Christianson, and G. Jacobsen, Reliability and Validity of the Ocular Surface Disease Index, Archives of Ophthalmology, vol.118, issue.5, pp.615-636, 2000.
DOI : 10.1001/archopht.118.5.615

C. Vitali, S. Bombardieri, and R. Jonsson, Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group, Annals of the Rheumatic Diseases, vol.61, issue.6, pp.554-562, 2002.
DOI : 10.1136/ard.61.6.554

S. Klein, R. Klein, and B. , Incidence of dry eye in an older population, Arch Ophthalmol, vol.122, pp.369-73, 2004.

W. Trattler, D. Katsev, and D. Kerney, Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys, Clinical Therapeutics, vol.28, issue.11, pp.1848-56, 2006.
DOI : 10.1016/j.clinthera.2006.11.016

G. Novack, Pharmacologic Treatments for Dry Eye, Cornea, vol.21, issue.1, pp.4-5, 2002.
DOI : 10.1097/00003226-200201000-00002

A. Behrens, J. Doyle, and L. Stern, Dysfunctional Tear Syndrome, Cornea, vol.25, issue.8, pp.900-907, 2006.
DOI : 10.1097/01.ico.0000214802.40313.fa

S. Rao, Topical Cyclosporine 0.05% for the Prevention of Dry Eye Disease Progression, Journal of Ocular Pharmacology and Therapeutics, vol.26, issue.2, pp.157-64, 2010.
DOI : 10.1089/jop.2009.0091

H. Perry and E. Donnenfeld, Dry eye diagnosis and management in 2004, Current Opinion in Ophthalmology, vol.15, issue.4, pp.299-304, 2004.
DOI : 10.1097/00055735-200408000-00004

C. Utine, M. Stern, and E. Akpek, Clinical Review: Topical Ophthalmic Use of Cyclosporin A, Ocular Immunology and Inflammation, vol.5, issue.2, pp.352-61, 2010.
DOI : 10.1097/ICL.0b013e3181b4d135

K. Kunert, A. Tisdale, and M. Stern, Analysis of Topical Cyclosporine Treatment of Patients With Dry Eye Syndrome<subtitle>Effect on Conjunctival Lymphocytes</subtitle>, Archives of Ophthalmology, vol.118, issue.11, pp.1489-96, 2000.
DOI : 10.1001/archopht.118.11.1489

K. Turner, S. Ugfelder, and Z. Ji, Interleukin-6 Levels in the Conjunctival Epithelium of Patients with Dry Eye Disease Treated with Cyclosporine Ophthalmic Emulsion, Cornea, vol.19, issue.4, pp.492-498, 2000.
DOI : 10.1097/00003226-200007000-00018

S. Tatlipinar and E. Akpek, Topical ciclosporin in the treatment of ocular surface disorders, British Journal of Ophthalmology, vol.89, issue.10, pp.1363-1370, 2005.
DOI : 10.1136/bjo.2005.070888

M. Lemp, Management of dry eye disease, Am J Manag Care, vol.14, pp.88-101, 2008.

S. Wilson and H. Perry, Long-term Resolution of Chronic Dry Eye Symptoms and Signs after Topical Cyclosporine Treatment, Ophthalmology, vol.114, issue.1, pp.76-85, 2007.
DOI : 10.1016/j.ophtha.2006.05.077

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=

K. Stonecipher, H. Perry, and R. Gross, The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca, Current Medical Research and Opinion, vol.21, issue.7, pp.1057-63, 2005.
DOI : 10.1185/030079905X50615

M. Rubin and S. Rao, Efficacy of Topical Cyclosporin 0.05% in the Treatment of Posterior Blepharitis, Journal of Ocular Pharmacology and Therapeutics, vol.22, issue.1, pp.47-53, 2006.
DOI : 10.1089/jop.2006.22.47

E. Toker and E. Asfuro?lu, Corneal and Conjunctival Sensitivity in Patients With Dry Eye: The Effect of Topical Cyclosporine Therapy, Cornea, vol.29, issue.2, pp.133-173, 2010.
DOI : 10.1097/ICO.0b013e3181acf68d

H. Liang, C. Baudouin, and P. Daull, Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound?healing model and an acute in vivo rabbit model, Mol Vis, vol.18, pp.2195-204, 2012.

. Sn, Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal, J Ocul Pharmacol Ther, vol.27, pp.603-612, 2011.

M. Sacchetti, F. Mantelli, and A. Lambiase, Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease, British Journal of Ophthalmology, vol.11, issue.8, pp.1016-1038, 2014.
DOI : 10.1016/j.jtos.2013.02.002

X. Zhang, C. Schaumburg, and T. Coursey, CD8+ cells regulate the T helper-17 response in an experimental murine model of Sj??gren syndrome, Mucosal Immunology, vol.172, issue.2, pp.417-444, 2014.
DOI : 10.1167/iovs.05-1382

K. Nichols, J. Nichols, and G. Mitchell, The Lack of Association Between Signs and Symptoms in Patients With Dry Eye Disease, Cornea, vol.23, issue.8, pp.762-70, 2004.
DOI : 10.1097/01.ico.0000133997.07144.9e